19.56
0.42 (2.19%)
| Previous Close | 19.14 |
| Open | 19.26 |
| Volume | 1,616,626 |
| Avg. Volume (3M) | 2,439,230 |
| Market Cap | 3,612,527,872 |
| Price / Earnings (Forward) | 51.81 |
| Price / Sales | 3.88 |
| Price / Book | 3.50 |
| 52 Weeks Range | |
| Earnings Date | 10 Mar 2026 |
| Profit Margin | -29.95% |
| Operating Margin (TTM) | -25.97% |
| Diluted EPS (TTM) | -1.18 |
| Quarterly Revenue Growth (YOY) | 107.50% |
| Total Debt/Equity (MRQ) | 35.65% |
| Current Ratio (MRQ) | 5.20 |
| Operating Cash Flow (TTM) | -263.30 M |
| Levered Free Cash Flow (TTM) | -202.32 M |
| Return on Assets (TTM) | -8.77% |
| Return on Equity (TTM) | -20.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Legend Biotech Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 1.88 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.31% |
| % Held by Institutions | 47.92% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Davern Capital Partners, Lp | 31 Dec 2025 | 1,056,668 |
| Matthews International Capital Management Llc | 31 Dec 2025 | 956,824 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (Barclays, 309.00%) | Buy |
| Median | 62.00 (216.97%) | |
| Low | 21.00 (TD Cowen, 7.36%) | Hold |
| Average | 58.71 (200.15%) | |
| Total | 6 Buy, 1 Hold | |
| Avg. Price @ Call | 19.80 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 11 Mar 2026 | 49.00 (150.51%) | Buy | 19.56 |
| RBC Capital | 11 Mar 2026 | 62.00 (216.97%) | Buy | 19.56 |
| 20 Jan 2026 | 66.00 (237.42%) | Buy | 23.42 | |
| Barclays | 04 Feb 2026 | 80.00 (309.00%) | Buy | 16.65 |
| HC Wainwright & Co. | 22 Jan 2026 | 50.00 (155.62%) | Buy | 19.34 |
| TD Cowen | 22 Jan 2026 | 21.00 (7.36%) | Hold | 19.34 |
| Oppenheimer | 07 Jan 2026 | 75.00 (283.44%) | Buy | 22.72 |
| Cantor Fitzgerald | 17 Dec 2025 | 74.00 (278.32%) | Buy | 21.42 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 21 Jan 2026 | Announcement | Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use |
| 12 Jan 2026 | Announcement | Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference |
| 17 Dec 2025 | Announcement | Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |